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Certain antibody neutralization escape mutants of HIV-1 map outside of the antibody recognition epitope, thereby sug-
gesting the presence of nonlinear conformational domains. In an effort to begin to define the interacting regions of the HIV
envelope proteins, a neutralization-sensitive clone of HIV-1, HXB2/BH10Sal-Bam, was passaged in the presence of the V3-
specific monoclonal antibody 0.5b. DNA sequence analysis of the V3 domain of the breakthrough viral populations revealed
one population that retained the parental V3 genotype. Quantitative DNA sequence analysis of this breakthrough population
revealed the presence of mutational ‘‘hotspots’’ in several envelope domains that are noncontiguous with V3. Mutations
were seen throughout gp41 and the C1, V1/V2, C2, and C5 domains of gp120. In contrast, other regions of gp120, C3, V4,
C4, and V5 remained totally unchanged. Within V1, three residues within a 14-amino acid stretch experienced five substitu-
tions and in C5 three residues within a 7-amino acid stretch experienced four substitutions. This finding, that certain residues
clustered within particular domains (V1/V2, C5, and gp41) experienced multiple substitutions under a defined environmental
stressor, suggests that the degree of adaptive plasticity exhibited by the HIV envelope is limited. Based on this observation
it may be possible, using a set of antibodies to various envelope epitopes, to discern a set of rules which explain the
interactions of the various envelope domains with each other and with their environment. The insight gained into the
physiologic constraints that the envelope proteins are subject to may be useful in developing therapeutic and vaccination
strategies. q 1996 Academic Press, Inc.
It has been previously demonstrated, both in vivo and Previous studies have generated neutralization-resis-
tant clones by growing HIV-1 under the selective pres-in vitro, that under the selective pressure of V3-specific
sure of broadly neutralizing heterotypic sera (7, 8). Resul-antibodies, HIV-1 neutralization escape mutants can be
tant viral clones were assayed for neutralization resis-isolated (1 – 4). Two types of breakthrough isolates have
tance, or sensitivity, by culturing them in the presencebeen described, those with mutations in the V3 loop itself
of panels of patient sera and monoclonal antibodiesand those where the amino acid changes occur at one
(MAbs) (9) that were capable of neutralizing the parentalor more sites distant from the V3 loop (5). In the latter
virus (10). A single amino acid change (A582T) in thesituation the loss of neutralization is not necessarily as-
extracellular domain of gp41 was noted to confer resis-sociated with a loss of antibody binding or even a de-
tance to CD4 binding domain antibodies giving credencecrease in the affinity of binding (4). These findings sug-
to the hypothesis that noncontiguous regions of the viralgest that the V3 loop contains a linear epitope, but that
envelope interact in the creation of functional domains.this epitope is part of a larger three-dimensional struc-
In the current study, an HIV-1 infectious molecularture that contributes to the formation of one or more
clone, which is exquisitely sensitive to neutralization byconformational domains. This hypothesis would suggest
the V3-specific monoclonal antibody (0.5b), was placedthat amino acids located within discrete regions through-
under selective pressure and the resultant breakthroughout the envelope may contribute to the formation of
population was examined via quantitative DNA sequencevarious 3-D functional domains (6), including those for
analysis. We chose this approach, rather than cloningvarious parameters of infectivity such as tropism, viral
isolates from the breakthrough population, in an effort tobinding, fusion and viral entry, and susceptibility to anti-
better observe points of flux throughout the envelopebody-mediated neutralization.
gene. This approach allowed for the detection of the
location, extent, and degree of change at a point and
within a region such that multiple replacements and their1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (412) 648-1916. E-mail: ehr@med.pitt.edu. ratios at a given site could be determined.
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The parental virus used in these studies was HXB2/ number of syncytia induced by virus inoculum in the ab-
sence of antibody.BH10Sal-Bam, an infectious molecular clone of HIV-1
constructed by cloning the SalI–BamHI env fragment of The HXB2/BH10Sal-Bam virus was demonstrated to
BH10 into an HXB2 background. Virus was expressed by be sensitive to neutralization by MAb 0.5b. In an effort
CaCl2-mediated transfection of purified plasmid DNA into to obtain neutralization-resistant populations of this virus,
H9 cells. Cell-free viral stocks were prepared by harvest- the contents of wells that evidenced viral breakthrough,
ing the supernatants from the virus-producing H9 cul- i.e., formation of 1–3 syncytia at the highest concentra-
tures at Days 7, 10, 14, and 18, and the stock with the tion (30 mg/ml or a 1:4 dilution) of 0.5b antibody, were
highest titer (Day 14) was used in subsequent neutraliza- centrifuged on Day 5 of the neutralization assay. The
tion studies. supernatants were incubated with 30 mg/ml of 0.5b and
the virus–antibody mixtures were then adsorbed ontoNeutralizing antibody assays were carried out using a
modified version of the protocol described by Nara and 2.3 1 105 MT-2 cells in a volume of 1 ml in 24-well
microtiter plate. After 6 days, syncytia were observed andFischinger (11) with the murine monoclonal antibody 0.5b
(12), which is specific for the V3 loop of the HIV-1 IIIB the contents of each well were transferred to a 12-well
plate. Fresh MT-2 cells were added and the selectivefamily of viruses. Briefly, 50 to 100 syncytia forming units
(SFU) of the titered HXB2/BH10Sal-Bam viral stock were pressure was maintained for an additional 2 weeks (25
days total), at which time five neutralization-resistantincubated with twofold serial dilutions of 0.5b in a 96-
well, V-bottomed microtiter plate (Costar). All experi- breakthrough virus populations were harvested.
ments were carried out in quadruplicate and included The V3 domains of the five breakthrough populations
virus-only positive controls. Fifty microliters of the virus – were screened by DNA sequence analysis. Proviral HIV-
antibody mixtures were used to infect DEAE-dextran- 1 DNA was extracted from the infected MT-2 cells by
treated (20 mg/ml) MT-2 cells. Cells were plated in poly- standard procedures, to serve as the template for PCR
L-lysine (Sigma)-treated 96-well flat-bottomed microtiter amplification of the HIV-1 viral envelope by the primers
plates (Costar) at a concentration of 5 1 104/well in 50 specified in Fig. 1. Amplifications were performed under
ml. The virus was allowed to adsorb to the cells for 60 full procedural safeguards as described (13–15) and
min at 377 in a humidified CO2 incubator. The inoculum sample blanks were included in all amplification runs
was then aspirated, and each well was fed with complete to test for the presence of carryover. The specificity of
RPMI 1640 medium. Wells were scored for syncytia on amplified products was determined by liquid hybridiza-
the fifth day after infection. Neutralization resistance was tion and gel retardation analysis followed by autoradiog-
determined by calculating the virus surviving fraction (Vn/ raphy (15–17). Both strands of the amplified products
were sequenced on an ABI 373A automated sequencingVo) at each dilution, where Vn represents the mean num-
ber of syncytia induced by the virus inoculum surviving system using Taq-based cycle sequencing with dye ter-
minator chemistry (Perkin–Elmer). Four of the five break-after neutralization, and Vo represents the mean of the
FIG. 1. Schematic representaion of PCR-based sequencing strategy for HIV env gene neutralization escape mutants. The numbered arrows
indicate the location and orientation of the primers used for amplification. Primer sequences and positions () were as follows; underlined nucleotides
represent changes which introduce restriction enzyme sites: 5750 TAC TTG GGC AGG AGT GGA AGC CAT (5727–5750); Mlu170 ATT GTT GTT
GGG ACG CGT ACA ATT AAT TTC TA (7144–7113); Mlu209 GAA ATT AAT TGT ACG CGT CCC AAC AAC (7115–7138); MluV5 TTC TCT CTG CAC
CAC GCG TCT CTT TGC CCT (7765–7736); Eag210 ATC TCC TCC TCC CGG CCG GAA GAT CTC GGA (7760–7631); Eag172 TCC GAG ATC TTC
CGG CCG GGA GGA GGA GAT ATG (7631–7660); Xho9028 GGT CTT AAA GGT ACC TGA GGT GTG ACT GGA (9028–8999).
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through populations were found to have mutations in the
V3 loop and were eliminated from further analysis. One
of the five exhibited no changes whatsoever in the V3
loop.
The neutralization phenotype of the breakthrough pop-
ulation that exhibited no DNA sequence alterations in
the V3 domain was determined using the quantitative
neutralization assay described above (Fig. 2). Assay re-
sults were compared with those for the parental virus,
HXB2/BH10Sal-Bam. The parental virus was 90% neutral-
ized at a 1:24 dilution, or 5.6 ng/ml, of antibody. In con-
trast, the breakthrough virus was resistant to neutraliza-
tion. At a MAb 0.5b concentration of 5.6 ng/ml, the Vn/Vo
FIG. 3. Relative distribution of predicted amino acid changes in the
breakthrough virus population. DNA sequence analysis showed that
codons for 18 different amino acid residues throughout the envelope
underwent mutation. Eleven changes were observed in the gp120, how-
ever, no changes occured within the V3 loop, the target of the selecting
antibody 0.5b, or in the four contiguous domains 3* of V3. A total of
seven changes were observed in gp41, three of which occurred in the
internal domain.
value for this virus population was 0.42, indicating only
58% neutralization. Even more notable was that, at higher
concentrations of antibody, there was greater divergence
between the Vn/Vo values of the parental virus and the
breakthrough virus. In contrast to its progenitor, HXB2/
BH10Sal-Bam, which had a Vn/Vo value of only 0.018 at
a 1:4 dilution of MAb 0.5b (29 mg/ml), the Vn/Vo value for
the breakthrough virus was 0.20. This represents a
greater than one log-fold difference in the number of
surviving virus particles in the breakthrough population.
Both strands of the gp120 and gp41 of the break-
through virus population were sequenced bidirectionally
and in their entirety, and the sequence compared with
that of the parental clone, HXB2/BH10Sal-Bam, in an ef-
fort to determine which noncontiguous regions under-
went mutation and selection. DNA sequence analysis
revealed that certain envelope domains had clusters of
mutations, whereas, in other regions, no changes were
observed. Translation of the DNA sequence analysisFIG. 2. The neutralization phenotype of the breakthrough virus popu-
lation was determined by a quantitative neutralization assay using the data predicted the accumulation of amino acid substitu-
selecting antibody, MAb, 0.5b. In this analysis, the breakthrough virus tions in the C1, V1/V2, C2, and C5 regions of gp120, as
population (m) was compared with its neutralization-sensitive parental well as both the intracellular and the extracellular regions
virus, HXB2/BH10Sal-Bam (j). Both the parental and breakthrough vi-
of gp41. The relative distribution of amino acid changesruses are identical at the antibody binding site, the tip of the V3 loop.
in this breakthrough population is demonstrated in Fig. 3.Neutralization resistance was determined by calculating the virus sur-
viving fraction (Vn/Vo) at each dilution, where Vn represents the mean Of interest, was the finding that V3 and its 3* contiguous
number of syncytia induced by the virus inoculum surviving after neu- regions C3, V4, C4, and V5 were all wild type with respect
tralization, and Vo represents the mean number of syncytia induced by to the parental clone. However, mutations identified at
virus inoculum in the absence of antibody. A 90% neutralization titer is
18 different codons throughout the remaining regions ofdemonstrated at Vn/Vo  0.01. The results represent the mean of two
the envelope gene, including gp41, would be predictedexperiments, with two data points recorded per experiment at each
dilution. to result in a total of 22 amino acid residue changes.
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TABLE 1
Amino Acid Residues in the Breakthrough Population Exhibiting Changes
Env protein Domain Mutation Extent of change Type of change
gp120 C1 T63K Complete Polar to basic
V1 C131C, Y, F, S 1:1:1:1 s|s to hydrophobic
V1 N141N, I 2:1 Loss of potential N-linked
Glycosylation site
V1 S144S, R 2:1
V2 E172D, Q 1:2 Acidic to uncharged
C2 N197N, D 2:1 Loss of potential N-linked
Glycosylation site;
*Uncharged to acidic
C2 A204A, G 2:1
C5 K487Q Complete Basic to uncharged
C5 K500K, T 1:1 Basic to uncharged
C5 A501A, T, P 3:2:1
C5 V506V, L 1:1
gp41 External G531G, A 1:1
External A582S Complete
External I642T Complete Hydrophobic to polar
External E657D Complete
Internal D773D, H 1:3 Acidic to uncharged
Internal A839G Complete
Internal R848T Complete
Mutations resulting in changes within 11-amino acid resi- nism of viral escape may be partially mediated by reduc-
ing the number of residues which are strongly interactivedues were seen in the C1, V1/V2, C2, and C5 regions of
gp120. In gp41, three of the seven amino acid residues with the immune system. Within the gp120 protein there
was: (1) an overall decrease in the number of chargedundergoing change were localized to the intracellular
domain. No changes were observed in the transmem- amino acid residues; (2) a net increase in hydrophobicity
in the V1 region; and (3) loss of potential N-linked glyco-brane domain.
Some of the mutant codons experienced complete nu- sylation sites in the V1 and C2 regions. These findings
suggest that ‘‘hotspots’’ exist within discrete regions ofcleotide replacements in the breakthrough population,
whereas other sites showed partial replacement with the envelope, including the internal domain of gp41, that
contribute to the creation of a neutralization escape phe-one to three changes occurring at various ratios. Table
1 demonstrates, by domain, the clustering of the amino notype from V3-specific antibodies.
In studies of immune-selected neutralization-resistantacid residues that have undergone mutations and indi-
cates the nature of each complete or partial amino acid escape mutants, it has been previously noted (4, 9, 10,
19) that a broad spectrum of distant site compensatoryreplacement. Two of the gp120 amino acid residues were
completely replaced by a single amino acid, and nine mutations can occur within both gp120 and gp41. In sup-
port of a functional interaction between gp41 and V3,were partially replaced by one or more amino acids.
Within the gp41 protein, five of the seven changes were Back et al., also reported the finding of mutations in both
the external and internal domains of the gp41 gene ofcomplete. Two of the four gp41 mutations that arose
in the extracellular region map to the putative gp120 HIV-1 clones made from V3-specific antibody neutraliza-
tion escape mutant populations (20). Thali et al., alsointeractive domains (18). It is interesting that three of the
sites that underwent mutation in gp41 map to the internal noted that a gp41 change conferred neutralization resis-
tance to broadly-reactive gp120 antibodies (21).domain. We have also found, through cassette mutagen-
esis studies, that the internal domain of gp41 contains The overall envelope structure within which the V3
domain is embedded appears to affect its neutralizationdeterminants that confer neutralization resistance on
HIV-1 IIIB family members (Sirko et al., unpublished re- phenotype by V3-specific antibodies and antisera. Rob-
ert-Guroff et al., demonstrated that enhanced, rather thansults 1994).
Many of the predicted amino acid changes in the reduced, neutralization occurred by exchanging V3 loops
between neutralization-sensitive isolates perhaps due tobreakthrough population result in the loss of interactive
groups from the envelope glycoproteins (charged, polar, the conformation-dependent exposure of normally con-
cealed epitopes (22). The structural conformation of theand glycosylated moieties), suggesting that the mecha-
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